Silence Therapeutics Plc Stock Market Outlook
| SLNCF Stock | USD 1.60 0.00 0.00% |
Roughly 54% of Silence Therapeutics' investor base is interested to short. The analysis of overall sentiment of trading Silence Therapeutics plc pink sheet suggests that many investors are impartial at this time. The current market sentiment, together with Silence Therapeutics' historical and current headlines, can help investors time the market. In addition, many technical investors use Silence Therapeutics plc stock news signals to limit their universe of possible portfolio assets.
Comfort Level 46
Impartial
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Silence Therapeutics' input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Silence Therapeutics plc.
News SentimentNeutral | Hype SentimentBearish | Insider SentimentWaiting |
Assuming the 90 days horizon and your above-average risk tolerance, our recommendation regarding Silence Therapeutics plc is 'Strong Hold'. Macroaxis provides Silence Therapeutics buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SLNCF positions.
Execute Silence Therapeutics Advice
The Silence recommendation should be used to complement the investment advice compiled from the current analysts' consensus on Silence Therapeutics plc. Macroaxis does not own or have any residual interests in Silence Therapeutics plc or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Silence Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Hold
Market Performance | Soft | Details | |
Volatility | Extremely Dangerous | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | High | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
For the selected time horizon Silence Therapeutics plc has a Risk Adjusted Performance of 0.0456, Jensen Alpha of 0.1752, Total Risk Alpha of (0.32) and Treynor Ratio of 0.1563We provide advice to complement the current expert consensus on Silence Therapeutics. Our dynamic recommendation engine harnesses a multidimensional algorithm to analyze the firm's potential to grow using all technical and fundamental data available at the time. To make sure Silence Therapeutics plc is not overpriced, please validate all Silence Therapeutics fundamentals, including its price to book, cash and equivalents, cash flow from operations, as well as the relationship between the gross profit and debt to equity . Please also confirm Silence Therapeutics plc shares owned by institutions to double-check your buy or sell decision is consistent with all fundamental data available and that the company can sustain itself in the current economic cycle.
Silence Therapeutics Trading Alerts and Improvement Suggestions
| Silence Therapeutics had very high historical volatility over the last 90 days | |
| Silence Therapeutics may become a speculative penny stock | |
| Silence Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 12.41 M. Net Loss for the year was (39.41 M) with profit before overhead, payroll, taxes, and interest of 4.96 M. | |
| About 57.0% of the company outstanding shares are owned by corporate insiders |
Silence Therapeutics current analysts advice
We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Silence analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Silence analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.
The consensus estimates and target price estimation comprises individual analyst assessments, and may or may not mutch the Macroaxis buy or sell advice. It is determined by taking an average of all analyst recommendations and classifying them as Strong Buy, Buy, Hold, or Sell.
Silence Therapeutics Returns Distribution Density
The distribution of Silence Therapeutics' historical returns is an attempt to chart the uncertainty of Silence Therapeutics' future price movements. The chart of the probability distribution of Silence Therapeutics daily returns describes the distribution of returns around its average expected value. We use Silence Therapeutics plc price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Silence Therapeutics returns is essential to provide solid investment analysis for Silence Therapeutics.
| Mean Return | 0.33 | Value At Risk | 0.00 | Potential Upside | 11.11 | Standard Deviation | 7.30 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Silence Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Silence Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Silence Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Silence Therapeutics' price will be affected by overall pink sheet market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Silence pink sheet's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | 0.18 | |
β | Beta against Dow Jones | 2.05 | |
σ | Overall volatility | 7.66 | |
Ir | Information ratio | 0.03 |
Silence Therapeutics Volatility Alert
Silence Therapeutics plc is displaying above-average volatility over the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Silence Therapeutics' pink sheet risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Silence Therapeutics' pink sheet price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Silence Therapeutics Fundamentals Vs Peers
Comparing Silence Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Silence Therapeutics' direct or indirect competition across all of the common fundamentals between Silence Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Silence Therapeutics or determine the pink sheets which would be an excellent addition to an existing portfolio. Peer analysis of Silence Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Silence Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Silence Therapeutics to competition |
| Fundamentals | Silence Therapeutics | Peer Average |
| Return On Equity | -1.43 | -0.31 |
| Return On Asset | -0.28 | -0.14 |
| Profit Margin | (2.24) % | (1.27) % |
| Operating Margin | (2.99) % | (5.51) % |
| Current Valuation | 240.14 M | 16.62 B |
| Shares Outstanding | 107.68 M | 571.82 M |
| Shares Owned By Insiders | 56.74 % | 10.09 % |
| Shares Owned By Institutions | 27.70 % | 39.21 % |
| Price To Earning | (17.50) X | 28.72 X |
| Price To Book | 8.36 X | 9.51 X |
| Price To Sales | 21.67 X | 11.42 X |
| Revenue | 12.41 M | 9.43 B |
| Gross Profit | 4.96 M | 27.38 B |
| EBITDA | (45.42 M) | 3.9 B |
| Net Income | (39.41 M) | 570.98 M |
| Cash And Equivalents | 51.56 M | 2.7 B |
| Cash Per Share | 0.57 X | 5.01 X |
| Total Debt | 52 K | 5.32 B |
| Debt To Equity | 0.02 % | 48.70 % |
| Current Ratio | 3.76 X | 2.16 X |
| Book Value Per Share | 0.95 X | 1.93 K |
| Cash Flow From Operations | 6.81 M | 971.22 M |
| Earnings Per Share | (0.53) X | 3.12 X |
| Target Price | 938.67 | |
| Number Of Employees | 105 | 18.84 K |
| Beta | 0.85 | -0.15 |
| Market Capitalization | 349.96 M | 19.03 B |
| Total Asset | 96.19 M | 29.47 B |
| Net Asset | 96.19 M |
Silence Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Silence . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Silence Therapeutics Buy or Sell Advice
When is the right time to buy or sell Silence Therapeutics plc? Buying financial instruments such as Silence Pink Sheet isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Silence Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Cannabis Thematic Idea Now
Cannabis
Equities that are involved in production and delivery of legal cannabis. This theme is designed for investors that are willing to accept higher levels of market risk inherited by cannabis production and distribution globally. The Cannabis theme has 30 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Cannabis Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Information and Resources on Investing in Silence Pink Sheet
When determining whether Silence Therapeutics plc offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Silence Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Silence Therapeutics Plc Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Silence Therapeutics Plc Stock:Check out Silence Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the CEOs Directory module to screen CEOs from public companies around the world.